SELLAS Life Sciences Group, Inc. Payments to Acquire Productive Assets
SELLAS Life Sciences Group, Inc. (SLS) reported Payments to Acquire Productive Assets of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-15.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireProductiveAssets · last filed 2017-03-15
- SELLAS Life Sciences Group, Inc. payments to acquire productive assets for the quarter ending 2015-12-31 was $0.00.
- SELLAS Life Sciences Group, Inc. payments to acquire productive assets for the quarter ending 2015-09-30 was $0.00.
- SELLAS Life Sciences Group, Inc. payments to acquire productive assets for the quarter ending 2015-06-30 was $34.00K.
- SELLAS Life Sciences Group, Inc. payments to acquire productive assets for the quarter ending 2015-03-31 was $500.00K.
- SELLAS Life Sciences Group, Inc. payments to acquire productive assets for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
- SELLAS Life Sciences Group, Inc. payments to acquire productive assets for fiscal 2015 was $534.00K, a 82.53% decline from fiscal 2014.
- SELLAS Life Sciences Group, Inc. payments to acquire productive assets for fiscal 2014 was $3.06M, a 80.32% decline from fiscal 2013.
- SELLAS Life Sciences Group, Inc. payments to acquire productive assets for fiscal 2013 was $15.53M.
| Period end | Payments to Acquire Productive Assets 3 month | Payments to Acquire Productive Assets 6 month | Payments to Acquire Productive Assets 9 month | Payments to Acquire Productive Assets 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-03-15 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $0.00 derived: sum of 2 quarters · filed 2017-03-15 | $34.00K derived: sum of 3 quarters · filed 2017-03-15 | $534.00K 10-K · filed 2017-03-15 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $34.00K derived: sum of 2 quarters · filed 2016-11-09 | $534.00K 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $34.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $534.00K 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | $500.00K 10-Q · filed 2016-05-10 | |||
| 2014-12-31 | $3.06M 10-K · filed 2017-03-15 | |||
| 2013-12-31 | $15.53M 10-K/A · filed 2016-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |